Transcriptomic Analysis and Optical Coherence Tomography Combined for Patients With Basal Cell Carcinoma

Image Markers and Transcriptome Profiles: an Exploratory Study of Optical Coherence Tomography and Tape Strips for Basal Cell Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06813833

Acronym

RNA-OCT-BCC

Enrollment

Registered

2025-02-07

Start date

2025-01-06

Completion date

2025-05-31

Last updated

2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basal Cell Carcinomas

Keywords

Basal Cell Carcinoma, Optical Coherence Tomography, Transcriptomics, Tape strip, Skin Cancer, Keratinocyte Carcinoma

Brief summary

The goal of this observational study is to learn if tape strip for transcriptomic (RNA) analysis and optical coherence tomography (OCT) combined can optimize noninvasive management of basal cell carcinoma (BCC) patients. The main question of the study is to examine if the combination of these two techniques, transcriptomic and OCT, can improve noninvasive detection of human BCCs. All included patients will undergo 1) an OCT scan and 2) a tape strip collection for transcriptomic analysis from the same BCC.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients \> 18 years with clinical suspicious BCC for inclusion in the study and BCC histopathology diagnosis for inclusion in our analysis.

Exclusion criteria

* Patients with a BCC in areas not amenable to OCT (e.g., around the eye).

Design outcomes

Primary

Measure	Time frame	Description
Association between tape strip and OCT	Single time point at baseline examination	The association between BCC-specific image marker profiles from OCT and BCC-specific transcriptomic profiles from tape strips, in histopathologically confirmed BCC patients.

Countries

Denmark

Outcome results